Left Ventricular Diastolic Dysfunction in Dialysis Patients Assessed by Novel Speckle Tracking Strain Rate Analysis: Prevalence and Determinants

Table 1

Baseline clinical characteristics of the total patient population and divided according to the presence (𝐸/SR_IVR≥236) or not (𝐸/SR_IVR<236) of significant left ventricular diastolic dysfunction.

	All patients (𝑛=77)	𝐸/SRIVR<236 (𝑛=40)	𝐸/SRIVR≥236 (𝑛=37)
Age (yrs.)	67.2±7.8	66.9±8.3	67.7±7.4
Male gender	57 (74.0%)	28 (70.0%)	29 (78.4%)
Hemodialysis	46 (59.7%)	19 (47.5%)	27 (73.0%)*
Dialysis vintage (months)	16 [9,34]	12 [8,26]	21 [10,52]
NYHA class
I	52 (68.5%)	30 (75.0%)	22 (59.5%)
II/III	25 (31.5%)	10 (25.0%)	15 (40.5%)
Hypertension	67 (87.0%)	31 (77.5%)	36 (97.3%)*
BSA	1.93±0.21	1.93±0.20	1.92±0.21
Diabetes mellitus	24 (31.2%)	8 (20.0%)	16 (43.3%)*
Myocardial infarction	21 (27.3%)	9 (22.5%)	12 (32.4%)
Hemoglobin (mmoL/L)	7.6±0.8	7.6±0.7	7.7±0.9
Creatinine (μmol/L)	649±203	650±230	648±174
Calcium (mmoL/L)	2.37±0.17	2.4±0.19	2.4±0.17
Phosphate (mmoL/L)	1.49±0.31	1.5±0.3	1.5±0.3
β-blocker	43 (55.8%)	22 (55.0%)	21 (56.8%)
ACEI/ARB	41 (53.2%)	22 (55.0%)	19 (51.4%)
Statins	55 (71.4%)	28 (70.0%)	27 (72.3%)
PWV (m/s)	10.9±3.3	9.6±2.8	12.3±3.3 *

* 𝑃<0.05 between patients with 𝐸/SR_IVR<236 and patients with 𝐸/SR_IVR≥236.
ACEI/ARB: angiotensin-converting enzyme inhibitors or receptor blockers; BSA: body surface area; NYHA: New York Heart Association; PWV: pulse wave velocity.